Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).
Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. Hájek R, et al. Among authors: rosinol l. Leukemia. 2017 Jan;31(1):107-114. doi: 10.1038/leu.2016.176. Epub 2016 Jun 24. Leukemia. 2017. PMID: 27416912 Free PMC article. Clinical Trial.
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J, Mateos MV, Palomera L, Fernández-Calvo J, Martí JM, Giraldo P, Carbonell F, Callís M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J; Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA). Bladé J, et al. Among authors: rosinol l. Blood. 2005 Dec 1;106(12):3755-9. doi: 10.1182/blood-2005-03-1301. Epub 2005 Aug 16. Blood. 2005. PMID: 16105975 Free article. Clinical Trial.
Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients.
Pérez-Simón JA, Sureda A, Fernández-Aviles F, Sampol A, Cabrera JR, Caballero D, Martino R, Petit J, Tomás JF, Moraleda JM, Alegre A, Cañizo C, Brunet S, Rosiñol L, Lahuerta J, Díez-Martín JL, León A, García A, Vazquez L, Sierra J, San Miguel JF; Grupo Español de Mieloma. Pérez-Simón JA, et al. Among authors: rosinol l. Leukemia. 2006 Mar;20(3):542-5. doi: 10.1038/sj.leu.2404085. Leukemia. 2006. PMID: 16408097 No abstract available.
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis.
Gutiérrez NC, Castellanos MV, Martín ML, Mateos MV, Hernández JM, Fernández M, Carrera D, Rosiñol L, Ribera JM, Ojanguren JM, Palomera L, Gardella S, Escoda L, Hernández-Boluda JC, Bello JL, de la Rubia J, Lahuerta JJ, San Miguel JF; GEM/PETHEMA Spanish Group. Gutiérrez NC, et al. Among authors: rosinol l. Leukemia. 2007 Jan;21(1):143-50. doi: 10.1038/sj.leu.2404413. Epub 2006 Oct 5. Leukemia. 2007. PMID: 17024116 Clinical Trial.
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
Rosiñol L, Oriol A, Mateos MV, Sureda A, García-Sánchez P, Gutiérrez N, Alegre A, Lahuerta JJ, de la Rubia J, Herrero C, Liu X, Van de Velde H, San Miguel J, Bladé J. Rosiñol L, et al. J Clin Oncol. 2007 Oct 1;25(28):4452-8. doi: 10.1200/JCO.2007.12.3323. Epub 2007 Sep 4. J Clin Oncol. 2007. PMID: 17785704 Clinical Trial.
Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Carreras E, Rosiñol L, Terol MJ, Alegre A, de Arriba F, García-Laraña J, Bello JL, García R, León A, Martínez R, Peñarrubia MJ, Poderós C, Ribas P, Ribera JM, San Miguel J, Bladé J, Lahuerta JJ; Spanish Myeloma Group/PETHEMA. Carreras E, et al. Among authors: rosinol l. Biol Blood Marrow Transplant. 2007 Dec;13(12):1448-54. doi: 10.1016/j.bbmt.2007.08.002. Biol Blood Marrow Transplant. 2007. PMID: 18022574 Free article. Clinical Trial.
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.
Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez N, Rosiñol L, Montejano L, Bladé J, Martínez R, de la Rubia J, Diaz-Mediavilla J, Sureda A, Ribera JM, Ojanguren JM, de Arriba F, Palomera L, Terol MJ, Orfao A, San Miguel JF; PETHEMA Study Group; GEM Study Group. Mateo G, et al. Among authors: rosinol l. J Clin Oncol. 2008 Jun 1;26(16):2737-44. doi: 10.1200/JCO.2007.15.4120. Epub 2008 Apr 28. J Clin Oncol. 2008. PMID: 18443352 Clinical Trial.
Pathogenesis and treatment of renal failure in multiple myeloma.
Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H. Dimopoulos MA, et al. Among authors: rosinol l. Leukemia. 2008 Aug;22(8):1485-93. doi: 10.1038/leu.2008.131. Epub 2008 Jun 5. Leukemia. 2008. PMID: 18528426 Review.
277 results